Sun Pharma and Pharmazz Inc. join forces to introduce Sovateltide (Tyvalzi™) in India

Sun Pharmaceutical Industries Limited has entered into a licensing agreement with U.S.-based biopharmaceutical company Pharmazz Inc. to bring Sovateltide, a groundbreaking drug for the treatment of acute cerebral ischemic stroke, to India. Sovateltide, to be marketed in India as Tyvalzi™ (Sovateltide), is the first-of-its-kind medication that can be administered up to 24 hours after the onset of stroke symptoms.

Under the agreement, Sun Pharma's subsidiary gains the rights to market Tyvalzi™ in India. Pharmazz will receive upfront payments, milestone payments, and royalties as part of the collaboration.
 

Kirti Ganorkar, CEO of Sun Pharma's India Business, is enthusiastic about Tyvalzi™'s potential: “The Phase 3 clinical trial for Tyvalzi™ demonstrated statistically and clinically significant improvements in neurological outcomes for ischemic stroke patients. It significantly extends the treatment window to 24 hours, compared to the current 4-5 hour limit for existing treatments.”
 

Dr. B. S. Paul, a prominent neuro-physician, highlighted the urgent need for new stroke treatments and emphasized Sovateltide's promise as it can be administered up to 24 hours after a stroke. Dr. Prof. Anil Gulati, the inventor of Sovateltide and CEO of Pharmazz, believes this partnership with Sun Pharma is a significant milestone in addressing India's stroke healthcare challenge.

Stroke is a major concern in India, with over a million estimated cases and ranking as the fourth leading cause of death and fifth leading cause of disability. This collaboration aims to provide effective stroke treatments, offering hope and improvement for stroke patients in India.